quest market share fight price
dragon reinstat buy po
nation provid clinic diagnost test
reinstat coverag market cap buy rate
po repres upsid potenti quest lead provid clinic
diagnost test relat servic deliv nationwid network
clinic lab patient servic center psc discuss
companion lab industri piec link clinic lab oper highli competit
price-deflationari environ howev see upsid potenti elev lab
consolid catalyz medicar reimburs cut pama retail clinic
opportun monet lab data although trend may slow
materi believ quest scale customer-fac mindset help
compani leverag core lab busi drive share gain margin expans
improv growth contract win themat defens
quest gain share due recent aet contract reshuffl
potenti gain hospit lab consolid longer term view
expect quest improv test mix posit quest expand
consum reach open psc retail pharmaci groceri store themat
quest benefit much less expos disrupt non-tradit healthcar
compani amazon us centric busi expos trade concern
moreov lab pure-play believ quest could potenti particip
event industri consolid us healthcar system becom
share trade adj ep est two year
forward histor averag last five two year
respect price object base adj ep
estim line quest averag price-to-earnings last two year risk greater
expect price headwind lower test volum growth competit well
econom execut integr data privaci regulatori risk
net dbt
pama protect access medicar act
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
largest provid clinic diagnost
test relat servic deliv
nation network full-servic clinic
laboratori patient servic center
clinic lab oper highli competit
price-deflationari environ howev see
upsid potenti elev lab consolid
catalyz medicar reimburs cut pama
retail clinic opportun monet lab
data although trend may slow
materi believ quest scale
customer-fac mindset help compani
leverag core lab busi drive share gain
margin expans
reinstat buy rate po
oper segment revenu breakdown
financi summari outlook
improv volum growth trend augment
oper margin recov depend cost save
reinstat buy rate po
reinstat coverag quest ticker buy rate
po repres potenti upsid octob
close quest lead provid clinic diagnost test inform
manag servic oper chiefli us nationwid
network full-servic clinic laboratori patient servic center
quest diagnost servic pure-play may help explain share
histor trade higher multipl chief competitor labcorp
despit averag lower organ volum growth howev quest enter
compani pois gain share follow open labcorp exclus contract
unit healthcar quest contract aetna also becom non-exclus next
year end result like net volum gain quest given
peopl coverag aet
top-line acceler well upsid potenti headwind
on-going medicar reimburs cut pama buffet lab industri catalyz
consolid opportun cut cost quest busi yet
optim labcorp defens characterist vs healthcar servic name
undemand valuat vs broader coverag univers drive buy
recommend moreov us healthcar system becom vertic
integr believ quest could potenti particip event industri
price object base price-to-earnings multipl line compani
averag two-year forward multipl last two year downsid risk
po increment price headwind govern commerci client
competit risk execut risk integr risk data privaci risk regulatori risk
net share gain due aet contract reshuffl
previous exclus quest aetna aet labcorp unit healthcar
contract becom non-exclus quest well-posit gain share
result contract reshuffl upsid opportun quest
outweigh potenti loss labcorp aet estim quest add
lab revenu contract reshuffl labcorp lose
compar lcd revenu
upsid potenti hospit lab consolid
headwind recent medicar reimburs cut pama buffet lab
industri believ nation clinic lab may opportun market
share upsid industri consolid expect signific portion
larg routin hospit test volum come sale next five ten
year hospit reconsid profit outreach busi model although
deal time difficult predict industri consolid could provid upsid quest
outlook increment revenu growth annual
margin volum upsid mix shift
given price headwind routin vitro diagnost test quest work
increas menu faster grow higher margin esoteric/specialti diagnost
addit quest work ancestri com provid dna test servic
boom consum genom market quest also work around employe
well strengthen recent medxm acquisit well blueprint well
offer employ among optum one compani largest custom
although still small part quest overal busi see mix shift help
improv margin time
limit exposur amazon trade disrupt
rel mani compani healthcar servic nation clinic lab
much less prone disrupt non-tradit vendor amazon enter
healthcar market moreov clinic lab like immun uncertainti
trade issu overhang life scienc compani coverag univers
quest servic revenu domest
quest unlik like main competitor labcorp sharpli diversifi busi
recent year acquisit two larg contract research organ
diagnost servic pure-play inde pure-play may help explain
share histor trade higher multipl lh share despit
averag lower organ volum growth moreov us healthcar system becom
vertic integr believ quest could potenti particip event
industri consolid like provid addit valuat support
theme consumer health care
open psc retail pharmaci groceri store quest expand
compani consum reach quest strategi combin expand access
patient given lab requisit go unfil reloc exist
psc exist brick-and-mortar retail site order downsiz quest nearbi
facil quest psc safeway store locat
pilot retail eventu quest see partnership
expand offer servic beyond tradit lab specimen collect
valuat less demand vs histor broader coverag univers
quest valuat attract rel peer broader coverag univers
price object base price-to-earnings multipl line compani
averag two-year forward multipl last two year
lower expect test volum growth competit risk
rel labcorp quest histor deliv lower organ volum growth
averag quest last year respect vs
labcorp suggest quest lost share said quest
organ volum growth acceler versu acquisit annual
quest pick increment share thank inclus contract
although quest labcorp recent shown better price disciplin
compani fierc competit contract chang possibl moreov
labcorp diversif cro market grow prowess data
analyt especi clinic trial match could potenti make labcorp
competit contract negoti
pama headwind well vet may bring commerci rate
discuss industri note link expect clinic lab market come
increas reimburs pressur pama quest see clf cut
medicar revenu lab busi overal revenu
would impact top-lin assum full
effect cut medicar revenu howev next wave govern rate
cut could larger expect medicar cut could eventu bleed
commerci space said evidenc aet contract open
quest labcorp show price disciplin past
lab industri consolid may take longer forecast
although expect consolid opportun hospit lab
structur may increas reimburs pressur pama hospit reach
medicar exposur vs quest consolid wave mani
industri invest commun expect could take longer expect
materi slow quest strategi specif lab typic
hospit net patient revenu may forefront hospit execut
agenda may take longer hospit manag make decis
regard smaller outreach lab let alon reason keep in-sourc
quest averag oper leverag sale growth
howev quest experienc neg oper leverag sever year
gross margin declin basi
back reimburs cut compound declin test volum gross margin
rebound organ volum growth expand
go forward current
model flat slightli gross margin top-lin growth
howev margin could erod expect core growth acceler
fda could impos stricter regul lab
measur fda regulate/limit use scope laboratory-develop
test ldt may result lower qualiti decreas test util increas cost
quest current ldt regul liber standard center
medicar medicaid howev indic fda
regulatori bodi could interest regul ldt futur regulatori
chang would present increas up-front develop cost note type
regul may weigh less well-resourc independ lab quest
labcorp vast major routin revenue test analyz
quest fda-clear
season weather econom impact
test volum usual declin year-end/holiday season well sever
weather condit natur disast volum also impact chang
econom condit patient may decid forgo routin visit doctor
time recess financi uncertainti
data privaci risk secur breach
data monet still small part revenu today clear quest
see tremend futur valu repositori hipaa health insur portabl
account act allow sale de-identifi patient data without
patient consent would nearli imposs re-identifi patient base
singl requisit form task becom exponenti easier increas
number data input think prudent consid risk futur
quest might requir obtain patient consent share de-identifi
health data may limit futur growth prospect valu proposit
payer patient data risk secur breach hacker attempt may result
misappropri patient identifi expos compani reput damag
larg fine
term price-to-earnings quest trade adj ep estim in-lin peer
labcorp exhibit histor averag multipl
last five two year respect two year forward basi exhibit
price object base price-to-earnings multipl appli
ep estim equat adj ev/ebitda estim
compani averag two-year forward ev/ebitda multipl
last five two year respect exhibit believ multipl
justifi given share gain compani defens natur rel mani
healthcar servic compani opportun capit deploy strateg
mn
exhibit histor clinic lab two-year forward price-to-earnings dgx year averag respect
exhibit histor clinic lab two-year forward ev/ebitda dgx year averag respect
headquart secaucu new jersey largest provid
diagnost test inform servic us deliv
nation network full-servic clinic laboratori patient servic
center psc quest public compani sinc today one
largest clinic lab provid perform diagnost test approxim
specimen annual includ routin lab test esoter test anatom patholog
quest market leader us independ clinic lab industri
share independ lab market highli fragment
us lab provid industri unlik main rival labcorp diversifi
market quest larg remain pure-play pleas see compani
report lab industri link in-depth discuss market competit
landscap outlook
oper segment revenu breakdown
quest oper two busi segment diagnost inform servic
provid routin lab test esoter anatom patholog drug monitor test
servic diagnost solut ds offer data manag system
electron health record product test risk assess servic
segment gener quest revenu quest revenu
deriv us compani see intern revenu reach
long run
chairman presid ceo stephen rusckowski serv ceo sinc
elect chairman board cfo mark guinan cfo
compani sinc rest quest team current
posit shorter time although senior leader compani
extend period
chairman presid
year current role
execut vice presid chief
execut vice presid group
senior vice presid group
senior vice presid chief
senior vice presid gener
mr rusckowski join quest presid chief execut offic may
elect chairman board decemb prior join
mr rusckowski ceo philip healthcar becam largest unit royal
philip electron leadership mr rusckowski also member board
director american clinic laboratori associ serv chairman
mr guinan join quest senior vice presid chief offic
previous mr guinan serv number financ oper role johnson
johnson serv chief procur offic earlier cfo
pharmaceut busi mr guinan held variou financi role procter
mr cunningham spent year inc prior join
mr cunningham serv variou role senior director world-wide learn
develop senior director busi oper vice presid sale
pharmaceut vice presid global corpor human
mr davi join quest senior vice presid group execut region
busi join quest serv ceo insightec inc prior
held vice presid gener manag role ge mri diagnost imag
healthcar inform technolog busi prior ge mr davi led develop
strateg oper initi client mckinsey
ms doherti join quest recent senior vice presid physician
servic busi prior ms doherti serv vice presid hospit servic
vice presid offic chairman
prior join januari ms eglinton manner two-decad
career span multipl product portfolio function busi
environ ms eglinton manner recent serv presid ceo ge
ms fonseca sinc lead enterprise-wid inform
technolog function support need busi previous ms fonseca
labcorp also held number senior leadership posit suppli chain
philip healthcar
mr prevoznik join quest acquisit smithklin beecham clinic
laboratori sbcl mr prevoznik serv vice presid gener
counsel sinc name senior vice presid prior join
smithklin beecham mr prevoznik repres sbcl outsid legal counsel
associ dechert price rhoad philadelphia
like share gain follow contract reshuffl
clinic lab market pois see increment share shift long stand
exclus contract becam nonexclus specif labcorp sign
exclus lab provid contract unit healthcar share
us commerci market extend quest follow
suit sign prefer provid contract aetna aet share us
commerci market today contract also came renew
net result contract open quest labcorp
opportun poach other formerli exclus territori howev sinc
live cover aet estim total lab spend
aet small percentag labcorp quest
like greater share shift quest labcorp inde quest note
contract open help compani move lower end
long-term revenu guid said would expect market shift
labcorp quest overnight quest alreadi larg unquantifi
busi psc footprint area limit
term price histor in-network deal made expens steep
discount quest labcorp highlight case
aet deal new contract impact price exist
busi though optumcar scenario analysi aet shift dynam
analysi refer industri note link
last decad quest labcorp significantli expand
oper merger acquisit labcorp chosen diversifi
new market becom lead cro contract research organ quest
acquisit strategi consolid us clinic lab market includ
hospit outreach regional/independ specialty/esoter lab specif quest
look acceler growth acquir busi expand compani
psc presenc complementari test capabl exhibit quest usual assum
top-lin growth although track around
us lab servic oxford immunotec
protect access medicar act pama pass swiftli without draw
much attent hospit lab industri like respons larg
medi-c settlement passag necessit cut medicar
spend off-set cost increas health insur coverag offic
inspector gener oig publish two report highlight
medicar overpay lab test rel rate charg commerci
payer pama dictat medicar outpati test base
lower commerci rate paid hospit refer lab servic
rate re-set clear neg entir lab industri near-term
ramif much sever hospit laboratori nation
clinic lab whose rate essenti establish baselin iron pama
cement complaint brought nation lab medi-c lawsuit
smaller refer lab could compet rate offer
hospit deal horizon
clinic lab industri extrem price market share pressur sinc
earli believ pama import catalyst shift tide back
favor larg nation clinic lab shift fee-for-servic capit
pay drove hospit outreach market nation lab turf pama effect
close door outpati test rate could drop mani hospit
smaller region lab next five plu year expect see
immedi seismic market shift expect see independ clinic lab
absorb signific test volum time more-than off-set pama-rel
price cut said pama near term headwind industri rate
continu declin next two year
quest strategi quest strategi regard includ target hospit outreach
lab acquisit refer test pl profession lab servic hospit
readi divest outreach busi quest may contract provid
refer test pl first eye toward cultiv relationship
futur deal summar quest hospit deal partnership sinc exhibit
small system new england
exhibit hospit deal partnership sinc
outreach acquisit half us hospit outreach program
hospit use inpati lab cost center provid clinic lab servic individu
physician offic healthcar system surround geograph area
in-hous lab
refer test hospit often send test unabl specialti genet
test unwil larger refer quest lead compani
market compani current work roughli half us hospit
pl quest launch profession lab servic pl busi way help
hospit run inpati laboratori effici quest pl offer includ
lab suppli chain manag outsourc accord quest pl save
hospit inpati lab oper cost
posit mix benefit increas molecular genom test
help off-set on-going price pressur routin test quest tri
shift offer mix toward specialty/esoter test molecular
genet test carri significantli higher margin much faster grow
market segment molecular diagnost mdx account
vitro diagnost ivd market exhibit grow high singl
digit vs low singl digit routin test
exhibit ivd market test type
exhibit mdx market test type
market diagnost intern bofa merril lynch global research estim
market diagnost intern bofa merril lynch global research estim
posit mix shift contribut roughli quest annual growth
period expect trend continu genom
infanc test menu expand inde last sever quarter lab
benefit increas uptak immunotherapi requir up-front
biomark test advanc specialti stain statu also see
signific white space opportun prevent genom goe
mainstream coupl carrier screen prior conceiv non-
invas prenat test nipt trisomi chromosom abnorm
move expand averag risk popul pregnant women
consum genom offer anoth tailwind growth
one fastest grow compon lab busi relat boom
consum genom market januari quest start provid genotyp
ancestrydna one largest consum dna test compani outsid
ancestri com relationship quest also pilot dtc test patient
missouri colorado arizona three state consum
order his/her lab test without physician consent accord
key supplier product sequenc servic consum genom industri
past year sinc incept consum genom product million
consum genom test conduct million complet
consum retail data initi earli intrigu
quest view consumer-fac busi invest signific
capit strateg energi expand consum outreach quest led
market open patient servic center pc safeway groceri store enhanc
reach direct-to-consum channel think slow process
see signific potenti especi consum increasingli take charg
quest strategi market combin expand access patient
captur unfil lab requisit reloc exist psc
exist brick-and-mortar retail set could drive downsiz
quest nearbi facil howev note cost save latter might
modest quest like still pay market rate rent number
quest current safeway locat nationwid quest
rel rapid push safeway benefit avail clinic space
locat safeway spent build clinic
supermarket offer blood test defunct start-up therano june
quest announc joint ventur collabor expect start
store allow signific locat growth time also
expand offer healthcar servic beyond tradit lab servic quest
also pilot retail notabl look see unfold
quest pend merger aetna move forward
quest also work around employe well strengthen recent medxm
acquisit total address market employe well program includ
peopl get insur employ quest blueprint
well offer employ custom manag employe well use
biometr screen identifi help risk provid health coaching/behavior
counsel connect employe healthcar provid
data data everywher one know think
anoth new growth driver monet lab data quest note
healthcar data analyt market worth today estim grow
compani billion lab-rel patient data point
use gener revenu outright sell raw de-identifi data use asset
win busi payer pharmaceut compani among other lab
data provid reason physician patient encount although may
possibl back base type test order exampl ct/ng
order alongsid pap test might indic well-woman visit lab data contain
detail prescript counter drug
quest also form joint ventur quintil iqvia follow merger
im largest cro earli call primari focu
partnership central lab servic quest share lab data iqvia
time time said consid data synergi iqvia
formal preferred/exclus relationship iqvia today given quest seem
interest find way furnish data directli pharma compani im core
compet would surpris see quest iqvia get cozier time
financi summari outlook
improv volum growth trend augment
shown exhibit histor quest organ lab volum growth rare
surpass labcorp acceler recent acquisit
annual quest gain share inclus contract estim
quest add lab revenu contract reshuffl
labcorp lose compar lcd revenu
offset volum gain increment reimburs pressur pama
quest expect see clf cut medicar revenu lab
busi follow said follow
announc may manag comment expect achiev
growth compound-annual-growth-rate high-end rang put forth
compani analyst day despit headwind pama expect
manag updat growth outlook compani next analyst day
novemb beyond note lab industri may come increas
level reimburs pressur next data collect period occur
preliminari rate comment novemb
exhibit quarterli organ lab servic volum growth comparison labcorp gener outpac quest
illustr exhibit quest averag annual total sale growth
last three year roughli remaind organ
compani see total sale growth pro-forma
sale organ manag
guid contribut annual
expect compani realiz annual contribut
overal see total sale growth
organ growth improv respect
exhibit expect quest sale grow roughli midpoint long-term guid
 vs guid organ growth line guid
shown exhibit quest maintain gross margin tight rang
even clf cut howev
gross margin contract partial driven
divestitur larg catalyz price pressur weak volum trend
organ volum declin gross margin rebound
organ volum growth expand recent account
updat result headwind gross margin compani
report uncollect balanc relat patient respons reduct net
revenu instead bad debt chang offset treatment cog
lower gm also lower oper margin
ebitda margin slightli effect bottom-lin go forward
expect gross margin remain roughli around
oper margin recov depend cost save
quest oper margin deterior alongsid
sever year success clf reimburs cut depict exhibit opm
trough basi sinc thank
invigor cost save program quest opm expand exit
on-going reimburs pressur govern commerci
payer quest reli continu cost save partnership revamp opm
profil pama expect see quest opm contract stay
essenti flat
sinc quest quintupl dividend per quarter howev thank
mid-singl free cash flow compound-annual-growth-rate dividend still less total
realloc expect dividend grow annual inde
despit worsen reimburs backdrop quest rais dividend
believ signal confid abil weather multi-
exhibit free cash flow alloc dividend buyback
dividend
buyback
given firm commit return major free
sharehold form dividend buyback combin necess
alloc capit inorgan growth opportun off-set pama cut slightli
concern quest abil continu gener strong cash flow
servic debt burden model
respect due dividend buyback debt payback
net cash flow estim
revenu
revenu
adj opex sale
intang asset amort sale
depreci sale
adj detail
revenu
dollar million except per share data
provis doubt account
asset liabil
oper
invest
financ
financ
net chang debt
dividend distribut
financ
begin period
end period
cumul decrease/increas
dollar million except per share data
equival
prepaid expens
properti plant equip net
current portion long term debt
total liabil equiti
dollar million except per share data
price object base price-to-earnings multipl line compani
averag two-year forward multipl last two year see upsid
potenti elev lab consolid catalyz medicar reimburs cut
pama retail clinic opportun monet lab data believ quest
scale customer-fac mindset help compani leverag core lab busi
drive share gain margin expans
upsid risk faster expect materi hospit lab consolid
trend margin expans due higher specialti test mix faster volum growth
consum genom trend
downsid risk greater expect price headwind lower expect test
volum growth competit execut risk integr risk data privaci risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
